Ongoing, recruitingTherapeutic confirmatory (Phase III)Interventional

I6T-MC-AMBZ - A Multicenter, Phase 3b, Open-Label, Single-Arm Study to Investigate Bowel Urgency and Its Relationship With Other Outcome Measures in Adults With Moderately to Severely Active Ulcerative Colitis Treated With Mirikizumab

At a glance

Status

Ongoing, recruiting

Phase

Therapeutic confirmatory (Phase III)

Sponsor

Eli Lilly & Co.

Enrolment target

116

Start

17 Jul 2023

Change from baseline in bowel urgency severity (UNRS) score at Week 12.

Age 18 Years to any · Sex: All

Always speak to your GP or specialist before deciding to take part in a study.